Corcept starts pivotal Cushing's syndrome study

Dec 20, 2007 (Datamonitor via COMTEX) -- CORT | charts | news | PowerRating -- Corcept Therapeutics has initiated Phase III trial with Corlux, a cortisol receptor antagonist, for the treatment of endogenous Cushing's syndrome.

In September, the company reported that the FDA had opened the investigational new drug application (IND) for Corlux for the treatment of endogenous Cushing's syndrome, which allowed it to initiate this 50-patient open label study. In the communication regarding the opening of the IND, the FDA indicated that a single study may provide a reasonable basis for the submission of a new drug application for the treatment of endogenous Cushing's syndrome.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index